Catalan biotech Iproteos has won the Expoquimia R+D+I Award in the Biotechnology category for the development of IPR19, a new drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.
The spin-off, founded by two IRB Barcelona scientists leaders in the field of therapeutic peptides, Teresa Tarrago and Ernest Giralt, expect to begin clinical trials of the compound in 2016.
Endowed with € 5,000 in each of their two categories -Biotechnology and Chemistry- the Expoquimia R+D+I Awards were delivered yesterday during the World Chemical Summit Night as part of the Expoquimia Exhibit at the Fair of Barcelona grounds.
Scientists at IRB Barcelona in collaboration with researchers at the University of Barcelona observe that aggregates of 20 to 100 units of beta-amyloid have a structure that is the most harmful to neurons.
This is the first time that a method allows scientists to monitor aggregation while simultaneously detect a structural pattern responsible for the toxicity of beta-amyloid aggregation.
The researchers state that these studies are a step towards finding a therapeutic target for a disease which, to date, has no treatment.
The Max-Bergmann-Society, a European-based organization of German, Swiss, and Austrian chemists, seeks to promote peptide research with a special emphasis on chemical methodologies.
Feature article published in the Spanish science news website Excelenciencia about the IRB Barcelona initiatives to bring closer the science to the society. The aim behind the new approaches included in the article are to inform and attracting new donations.
Atraer donaciones con un clic (in Spanish)
Alzheimer’s disease has no cure and virtually no palliative treatments are available. Even today its origin is still unknown. All this has driven the international scientific community to back new approaches that allow early diagnosis of the disease and the discovery of a treatment to stop its progression. IRB Barcelona is not oblivious to this tendency. The researchers Patrick Aloy and Natàlia Carulla head projects addressing an alternative slant on the control and progression of the disease and the discovery of new therapeutic agents.
The coordinator of Chemistry and Pharmacology Programme at IRB Barcelona is presented with the Josef Rudinger Memorial Lecture Award during the European Peptide Symposium, in Sofia, Bulgaria.
The award is in recognition of longstanding contributions to the field.
Several media echo on the research lead by Ernest Giralt focused on the use of wasp venom as a strategy to kill cancer cells selectively.
News of the Spanish Scientific News Agency, SINC Agency, on a study perfomed at Ernest Giralt's lab with wasp venom to desing a new therapyagainst breast cancer.
The laboratory of Peptides and Proteins, headed by Ernest Giralt , published in the Journal of Controlled Released a therapy for breast cancer using the wasp venom. The August magazine of “Muy Interesante” has echoed the study.
Around 160 scientists, brought together by IRB Barcelona and the BBVA Foundation in a Barcelona Biomed Conference, are discussing the latest research into one of the hallmarks of Alzheimer’s disease, the amyloid-beta protein that is the major component of the plaques that are characteristic of this debilitating disorder.
According to data from Alzheimer's Disease International in 2013, an estimated 135 million people worldwide will be suffering from dementia in 2050, Alzheimer’s disease being the most prevalent. This condition currently affects over 40 million people but is very strongly age-related, giving rise to the prospect of a ‘21st century plague’ affecting the aging populations across the globe.
A recent report from the Cleveland Clinic published in July 3, indicates that 99.6% of the clinical trials for Alzheimer´s disease have failed, with the result that much of the pharmaceutical industry is discouraged and uncertain as to how to proceed. The scientific community, however, is making substantial progress in understand the underlying causes of the disease, an essential factor in the rational design of innovative therapeutic strategies.